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Abstract
Evidence-based medicine (EBM) can be defined as the integration of optimized clinical
judgment, patient values, and available evidence. It is a philosophical approach to making
the best possible clinical decisions for individual patients. Based on objective evaluation
and categorization of methodological design and data quality, all existing literature can be
organized according to a hierarchy of “evidence quality” that helps determine the appli-
cability and value of scientific findings in terms of clinical implementation and the poten-
tial to change existing patterns of practice. In terms of general categorization of scientific
impact, randomized controlled trials (RCTs) are placed on top of the hierarchy, followed
by systematic reviews of randomized controlled trials (RCTs), quasi-randomized designs,
observational studies including retrospective case series, and finally case reports and
expert opinion. Each study design is susceptible to certain limitations and biases,
highlighting the importance of both clinical and scientific acumen of the interpreting
provider. Such approach is critical to determining the value and the applicability of study
recommendations in everyday practice. Evidence-based practice (EBP) has become one of
the fundamental components of modern medicine and plays an indispensible role in the
development (and improvement) of patient care and safety worldwide. Furthermore,
organizations that create guidelines and policies for the management of specific condi-
tions, often base the content and strength of their recommendations on the quality of
evidence available to expert decision-makers. Therefore, understanding the “state of the
science” upon which those recommendations are based will help guide the medical
practitioner on “if, when and how” to apply evidence-based guidelines in his or her
everyday medical or surgical practice. This chapter focuses on clinically relevant applica-
tion of levels of scientific evidence (LSE) and the corresponding levels of clinical recom-
mendation (LCR) in the context of care quality and safety.
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1. Introduction
Evidence-based medicine (EBM) is a scientific approach to clinical problems, intended to help
clinicians make the best possible decision for their patients, and the “best decision” being
defined as one that incorporates the relevant evidence applied through the expertise of a
practitioner while preserving patient autonomy and safety [1, 2]. At its core, EBM combines
two fundamental principles. First, evidence by itself is never sufficient to make a clinical
decision and should be combined with clinical expertise and adapted to each patient’s unique
case. Second, practitioners need to be aware how much confidence can be placed in a particu-
lar recommendation, thus creating the need for establishing pre-determined levels of scientific
evidence (LSE) to help guide the decision-making process [2].
During the past two decades, the introduction of EBM has contributed to a dramatic shift in
clinical practice patterns [3–5]. Wide-scale implementations of EBM principles across institu-
tions formed a foundation for better and more streamlined decision making among physicians,
contributing to gradual improvement in both patient safety and quality of care [6, 7]. Perhaps
just as importantly, such paradigms led to an increased ability for individuals and systems
alike to undergo self-evaluation and self-improvement [8, 9]. As the overall quantity and
quality of available clinical scientific evidence increased over time, applications of this knowl-
edge led to enhancements in various clinical processes, directly and indirectly improving the
safety record of healthcare institutions that embraced EBM-based models [10, 11].
Any experimental observation suggesting a relationship between two clinical variables consti-
tutes some form of scientific evidence. The “strength” of that evidence is determined by the
total number of measurements, the degree of any observed correlation, ability to reproduce
results, as well as the methodology used to collect and analyze information [12–14]. It is
important to note that the availability of multiple sources of information in a specific area
may allow for cross-correlation of results and greater decisional confidence when making
recommendations. It then behooves clinicians to understand both the strength of recommen-
dations, which is inherently variable due to heterogeneous methodological approaches, and
the applicability of results to a particular patient which is derived through a deeper under-
standing of how the evidence was obtained [2, 15]. Based on the quality of study design,
estimated level of bias, overall validity, and clinical applicability, standardized definitions of
“levels of evidence”were introduced to help reduce errors and to make better, more consistent
clinical decisions [4, 16]. Tables 1 and 2 demonstrate commonly utilized levels of scientific
evidence and grades of recommendation, respectively [17]. Grades of recommendation (GOR)
are discussed in more detail in subsequent sections of this chapter.
Currently, the best available evidence in any particular clinical area is heavily dependent on the
issue being researched, the difficulty of obtaining adequate data (which may be based on the
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prevalence, incidence, or even our understanding [or lack thereof] of a particular disease), and
the type of scientific question being asked (e.g., clinical prognosis, treatment effectiveness, and
risk-benefit assessment) [4, 18–20]. However, when it comes to issues of therapy or treatment,
randomized controlled trials (RCT) and systematic reviews of RCTs are generally considered to
be the “gold standard” with the highest internal validity and least amount of bias [14]. On the
opposite end of the spectrum, non-systematic observations, ideas, and editorial opinions made
by individual clinicians are considered to be the weakest form of supporting evidence in the
context of formulating subsequent recommendations [3, 21]. The hierarchy of LSE, broken
down by the type of research endeavor, is presented in Figure 1 [9, 22].
The practice of EBM provides clinicians with a clear, concise course of action, encouraging the
formulation of a relevant clinical question, finding and critically assessing the best available
evidence, and applying pertinent results into clinical practice with the fundamental goal of
improving patient outcomes, safety, and overall quality of care [23–25]. As outlined in Table 1
and Figure 1, available evidence may range from an RCT to isolated observations or opinions
of single individual. While all existing evidence is not considered equal, it is critical to
LSE Type of supporting scientific data
Ia High-level evidence derived from meta-analyses of RCTs
Ib Scientific evidence obtained from at least one high-quality RCT
IIa Evidence obtained from at least one well-designed, non-randomized CT
IIb Evidence obtained from at least one well-designed, quasi-experimental study
III Evidence based on well-designed observational (e.g., case-control, correlation, or comparative) studies
IV Evidence based on documented opinions of experts, committees of experts, and/or clinical experiences of opinion
leaders in a specific topic area
CT, clinical trial; LSE, level of scientific evidence; and RCT, randomized clinical trial.
Table 1. Broadly accepted classification of levels of scientific evidence.
Grade LSE Corresponding recommendation
A Ia, Ib Grade A recommendations require at least one RCT as part of the overall scientific evidence. In
addition, good overall data quality and consistency of results must be present
B IIa, IIb, and
III
Grade B recommendations require methodologically sound CTs (that are not RCTs) as part of the
overall scientific evidence used during the formulation process. Grade B recommendations are
based on the most heterogeneous grouping of evidence (IIa, IIb, and III)
C IV Grade C recommendations are usually built upon a careful compilation of expert opinions and/or
clinical experiences of respected opinion leaders in a specific topic area. In global terms, Grade C
recommendations indicate the absence of high quality clinical studies (e.g., suitable CTs or RCTs)
CT, clinical trial; LSE, level of scientific evidence; and RCT, randomized clinical trial.
Table 2. Grades of recommendation, from highest (A) to lowest (C), are primarily based on the level of available
scientific evidence.
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understand that all LSEs are important and have their own intrinsic value that corresponds to
their level of clinical relevance and overall impact on patient care [26].
In this chapter, we outline different LSEs and associated study designs, followed by a detailed
discussion on implementing clinical research findings in the context of GOR. Finally, we
consider adaptation of evidence-based practice to improve both quality of care and patient
safety across our health systems.
2. Levels of evidence: the importance of study design
Therapeutically relevant clinical research evidence can be broadly categorized into studies of
an observational nature and those that have a structured experimental study design [4, 27].
Experimental studies, which include randomized controlled trials (RCTs) and methodologi-
cally sound meta-analyses of RCTs, are positioned at the top of the hierarchy (Figure 1 and
Table 1) [3]. Although nomenclature may change across different categories of research (e.g.,
experimental, qualitative, outcome, or descriptive), the fundamental premise of LSE stratifica-
tion remains the same—an organized progression from “low to high” along the spectrum of
internal/external scientific validity (and repeatability) [28–32].
Bias in a study design can confound results of an investigation and lead to misrepresentation
of the true implications of the intervention/treatment being studied [33]. An RCT is a clinical
trial design intended to minimize bias by randomly allocating study participants to two or
more interventions or treatment “arms” [14, 34] and often “blinding” patients and investiga-
tors from knowing which intervention an individual is receiving. Within this paradigm, each
treatment arm may represent a different drug, device, or a procedure. It may also represent
different ways of applying or using a process, device, a procedure, or a placebo. By limiting
any opportunity for patients, clinicians, or investigators to choose which arm of the trial the
Figure 1. Levels of scientific evidence according to different types of study. For each category of research (e.g., experi-
mental, qualitative, outcome, or descriptive), the red arrow indicates the increasing level of scientific evidence, manifested
through greater internal, external, and quantitative result validity. Modified from Tomlin and Borgetto [22].
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participants will be assigned to, RCTs effectively minimize bias through the process of ran-
domizing both known and unknown prognostic variables [4, 18, 35, 36]. The above-mentioned
“blinding” process thus allows a “less biased” estimate of the treatment effect that has enabled
RCTs to revolutionize medical research, achieving the status of “gold standard” for therapeutic
research and holding the top position in the EBM hierarchy of LSEs (Table 1 and Figure 1)
[37, 38].
Results from RCTs, although considered the most robust and reliable form of evidence, are not
always easily translatable or applicable across diverse clinical settings. Moreover, not every
medical decision requires data from an RCT [39]. Implementation of RCT findings may be
challenging at a single-institution level, primarily because of procedural, work-flow, and other
institution-specific factors [2, 40].
Well-designed observational studies are recognized as level IIa, IIb, or III evidence (Table 1)
and generally are easier to conduct than an RCTs, but still provide meaningful clinical evi-
dence [37, 41]. Additionally, observational studies may lay the foundation for the definitive
RCT to be conducted. Cohort and case-control studies are the two primary types of observa-
tional studies that can demonstrate important associations between exposure and disease [37].
Placed slightly above case-control studies on the LSE hierarchy, cohort studies can be both
prospective and retrospective in nature [37, 42]. Prospective cohort studies observe two groups
of populations—one group with the risk or prognostic factor of interest and the second group
without [9]. These populations (or groups) are followed over a variable period of time to
observe the development of a disease or a specific outcome among those with the risk factor
and those without. Prospective cohort studies can be tailored to collect data regarding expo-
sure to any specific or rare disease and can be designed to observe multiple outcomes for any
given exposure or intervention [37, 43]. Retrospective cohort studies, on the other hand, are
historic in nature and look in to the past to analyze disease development within a specific
group of subjects based on their known (or declared) exposure status. Retrospective cohort
studies are more economical to conduct compared to prospective studies and take a shorter
amount of time to complete, although the results from such studies may be incomplete or
inaccurate [37, 44, 45]. They may also have advantages in terms of utilization of large national
data sets to help analyze and derive relationships that may answer or pose new clinical
questions.
In contrast to cohort studies, case-control studies recruit subjects based on the outcome of
interest at the outset of the study [46, 47]. Subjects with a specific outcome are categorized as
“cases” and subjects without the specific outcome are categorized as “controls” [47]. Retro-
spective data regarding the presence of exposure to single or multiple risk factors are then
collected from both groups, typically by conducting interviews, surveys, or collecting chart
data. Based on the collected data, strength of association between disease and exposure may be
determined and provided in the form of odds ratio or relative risk [4]. Case-control studies can
provide valuable information about rare diseases or those ailments that have a prolonged
latency period [4, 37, 44, 45].
Case series, case reports, and expert opinion constitute the lowest quality evidence on the
overall hierarchy of LSE, are inherently retrospective in nature, and most often feature no
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control or comparison groups (or cases) [48]. These reports are usually narrow in scope,
describe a single population subgroup, and are often based on the experiences of an individual
researcher or a single institution. The above-mentioned factors render data within the latter
LSEs less reliable, possibly difficult to reproduce, and often non-generalizable when applied to
a larger (or different) population. Such studies, however, can provide useful information on
rare diseases or unique presentations and complications associated with particular interven-
tions or procedures [4, 49–51].
The practice of EBM requires deep and critical analysis of the entire body of available evidence
in a specific area, with more fragmentary assessments being considered improper and inade-
quate [15, 52]. Systematic reviews are a key component of evidence-based health care, and are
defined loosely as “secondary analyses” of a large collection of reported results from individ-
ual studies for the purpose of integrating the overall findings [53, 54]. Systematic reviews
essentially use data from individual studies (most often RCTs) and “pool” these data together
to draw a more robust conclusion regarding the effect of the intervention being researched on
specific clinical outcome(s) [4, 19, 55]. The primary aim of systematic reviews is to determine
whether an effect exists and if that effect is negative or positive in relation to a specific clinical
approach or intervention vis-à-vis a pre-defined outcome [54]. By “pooling” data and results
from multiple studies, well-designed systematic reviews can answer questions that cannot be
sufficiently answered by any individual study [56]. In addition, this approach clearly demon-
strates any discrepancies between apparently conflicting studies. Finally, systematic reviews
can also be used to generate new hypotheses [54, 57].
Having described the different levels of evidence, it is important to note that the LSE hierarchy
is not “set in stone” and a number of factors determine the validity and strength of any
particular research study and consequently the evidence. Key elements within study method-
ology, such as patient inclusion or exclusion criteria, play a critical role not only in determining
the level of evidence attributable to any particular finding but also the applicability and
translatability of study results to any particular patient or institutional setting. The recognition
of inherent biases based on the study setting, financing source(s), and the appropriateness of
the statistical analysis plan is important when determining the validity of results. Subsequent
sections of our chapter will provide a practical discussion on the practical application of LSEs
in the clinical arena, focusing specifically on patient safety and quality of care as well as the
role of different grades of recommendations (GOR’s) in understanding the implementation of
evidence in a particular setting or situation.
3. Levels of scientific evidence: clinical applications and examples
In order to better understand how LSEs are relevant to GORs and EBM, some practical clinical
examples are provided below to help clarify these important scientific relationships and
associations. Further discussion of GORs and implementation paradigms for clinical scientific
evidence (e.g., 5A’s, P-D-C-A, Figures 2 and 3, respectively) will then follow, with focus on
fostering organizational excellence and a culture of safety [58–60].
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Figure 2. Schematic representation of the PDCA (Plan-Do-Check-Act) cycle. Each iteration of the cycle involves a number
of procedural checkpoints, with specific sets of associated tasks and critical questions.
Figure 3. The evidence-based medicine cycle begins with Assessment (e.g., determination of need for a new cycle/process).
This is followed by Asking pertinent questions (e.g., reasonably answered and searchable issue) and Acquisition of data
(e.g., existing literature and targeted de novo gathering of information). The next step is the Appraisal (e.g., critical
evaluation of all available data in the context of the primary question and the quality/levels of evidence), and finally,
Application of the newly synthesized evidence into existing institutional/patient care matrix. Based on the overall outcome
of the currently completed cycle, as well as the institutional needs and areas of focus, the determination of “if/when” to
begin next cycle is made [143, 148].
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Our discussion will begin with a relatively recent account of clinical investigations into a
hypothesized association between silicone breast implants and lymphoma [18, 61–64]. Given
the growing number of anecdotal case reports regarding observations of lymphoma following
silicone breast implantation, several retrospective cohort studies with large numbers of sub-
jects were conducted, including many years of follow-up data [18, 65–67]. An association was
reported in some studies, but no statistically significant conclusion could be drawn, suggesting
that in order to demonstrate any linkage between silicone breast implants and lymphoma, a
greater LSE will be required. When a high-quality systematic review was performed by
combining data from all retrospective cohorts, no significant association was shown between
silicone breast implants and the development of lymphoma [63]. This particular story high-
lights the importance of LSEs and the potential for patient harm (economic, physical, and
psychological) when available data are insufficient to make specific clinical management
recommendation(s) [68, 69]. At the same time, one might also make an argument that further
research is required to increase the certainty of the relationship between variables under
scrutiny, but this approach may not be feasible for very rare conditions or occurrences due to
various ethical, patient safety, and statistical considerations [18].
Another example where ethical, financial, and patient safety considerations preclude the
conduct of any prospective, randomized research is the area of retained surgical items (RSI)
[56, 70]. The retention of surgical instruments is an extremely rare complication, and thus, any
study of methods to prevent this dreaded occurrence would need to be prohibitively large to
have the power to show a statistically significant advantage of any particular approach over
another. At the same time, justification for prospectively comparing specific interventions or
the differential application of protocols/procedures related to RSI risk is ethically questionable
at best. Consequently, a meta-analytic study of all existing case-control reports on the topic of
RSI was performed, effectively demonstrating that pooled data from three source studies
identified potential risk factors for RSI that were not apparent from each individual study
[56]. While source reports individually suggested that between 3 and 6 variables may be
associated with greater incidence of RSI [70–72], the combined report showed that 7 of 11
potential risk factors were significantly associated with elevated odds for RSI [56]. The above
exercise in knowledge synthesis shows that carefully implemented meta-analytic approaches
can result in better understanding of an important area of patient safety.
Moving to a different patient safety topic, case-based experiences from the 1950s led physi-
cians to avoid epinephrine injections during hand/finger procedures due to concerns for
ischemic complications [18, 73]. Despite the absence of higher level of evidence, avoidance of
digital epinephrine injections was widely practiced and taught during that time. Eventually, a
comprehensive review of literature between the years 1880 and 2000 was performed, highlight-
ing 48 cases of digital infarction, 21 of which involved epinephrine injections [73]. Subsequent
to that, a number of cohort studies were published, reporting no significant association
between digit ischemia and local epinephrine injections [74–76]. Based on the conclusions
drawn from studies with higher LSE, the original hypothesis was rejected [18]. This example
demonstrates how observational and case studies may be inherently biased and that higher
levels of scientific evidence must be available before making any definitive conclusions,
accepting evidence as fact, and implementing evidence-based recommendations [18].
Vignettes in Patient Safety - Volume 360
In contrast, even well-conducted RCTs are sometimes unsuccessful in swaying medical prac-
tice. The University Group Diabetes Program trial, a methodically sound RCTconducted in the
late 1960s found lack of efficacy of an anti-diabetic drug tolbutamide compared to diet alone in
prolonging life. Furthermore, the study suggested that tolbutamide is less effective than
diet alone or diet with insulin as a modulator of cardiovascular mortality [77, 78]. Despite
relatively high LSE presented in the study, tolbutamide prescriptions increased, as debate over
the trial’s interpretation continued for more than a decade [78–80]. Similarly, the Antihyper-
tensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) showed that
thiazide diuretics were as effective as modern (and much more expensive) calcium-channel
blockers and angiotensin-converting-enzyme inhibitors in treating hypertension [81]. These
finding were questioned by pharmaceutical companies, and after an initial resurgence of
thiazide prescriptions following the trial’s publication [82], the sales of newer antihypertensive
agents increased [38, 83–85].
All of the above examples show that no single study can provide definitive answers or
understanding of therapeutic response, diagnostic test efficacy, or disease-specific risk factors.
The struggle continues between the forces of clinical habit, third-party interests, and objective
evidence. Policy-makers, opinion leaders, and providers must embrace both open-mindedness
and the value of unbiased research in guiding EBM and evidence-based recommendations
[86–88]. Likewise, all healthcare providers must be well versed in both the definitions and the
application of the concepts of LSE, GOR, and EBM and must recognize that there are multiple
factors at play when deciding which evidence is best and how to apply this evidence [87–89]. It
has been proposed that misapplication of clinical scientific evidence may be one of the key
barriers to sustainable improvement in healthcare quality and safety in a highly complex
system with increasingly constrained resources [87, 89, 90].
4. Important limitations
Recommendations from various expert groups are based on different LSEs, ranging from ran-
domized controlled trials to so-called expert opinions, and all come with their own set of limita-
tions that should be considered when transforming research findings into clinical practice. After
defining and discussing important aspects pertaining to different LSEs, we will now touch upon
some of the pitfalls associated with implementing and following EBM in every day practice.
Introduced as an effort to reduce bias and improve the accuracy of evidence, RCTs have
expanded medical knowledge and transformed clinical practice [3]. While RCTs are consid-
ered to provide the most internally valid evidence, not all RCTs are methodologically sound
and often offer only partial answers. In their “Evidence Based Medicine Manifesto for Better
Healthcare,” Heneghan et al. [91] state that “too many research studies are poorly designed or
executed. Too much of the resulting research evidence is withheld or disseminated piecemeal.
As the volume of clinical research activity has grown the quality of evidence has often wors-
ened, which has compromised the ability of all health professionals to provide affordable,
effective, high value care for patients” [91]. In addition, RCTs are very challenging to execute,
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are costly, and have long latency periods. This may have important implications during study
design, especially when establishing appropriate inclusion criteria or standardizing experi-
mental interventions [3, 4, 18, 38]. Limitations and challenges associated with RCTs have
forced physicians to look into alternate study designs that are easier to conduct, take less time
to complete, are less expensive, and yield similar results to RCTs [2].
Perhaps the most commonly employed tool that allows researchers quickly and effectively
leverage the wealth of existing evidence from various RCTs is meta-analysis [88, 92, 93].
Having said that, systematic reviews including meta-analyses can generate secondary evi-
dence that is only as good as the cumulative evidence provided by primary source studies
[15, 52]. Therefore, the validity of evidence from systematic reviews is largely based on the
RCTs included, and meta-analyses cannot ameliorate any biases present in source studies [15].
Moreover, systematic reviews and meta-analyses rely solely on published data and evidence,
some of which may be published in obscure journals and not easily accessible. In addition,
some of the reported data may be limited in scope, with heterogeneous reporting of outcome
parameters. This phenomenon is called publication bias, and in order to minimize such a bias,
researchers are advised to search literature thoroughly and methodically as well as maintain
contact with both study authors/investigators and other experts in the field [15].
Observational studies, including case-control and cohort designs, come with their own set of
limitations and biases [94, 95]. Case-control studies draw a comparison between individuals with
a condition or disease (cases) and those individuals in whom the condition or disease is absent
(controls), optimally in a fixed ratio of cases and controls (e.g., 1:2, 1:3, or 1:4) [14]. Since both
groups are compared with respect to their past and present exposures, most of the information
provided relies on recall and may end up being incomplete or even untrue [47]. In addition,
validation of the collected information may be extremely difficult or not feasible, and a detailed
study on the mechanism of the researched disease is rarely possible. On the other hand, cohort
studies select a group of individuals with certain characteristics and follow them over a long
period of time for the development of a particular disease or outcome of choice [96]. Since cohort
studies are usually conducted over extended periods, key challenges include high study costs and
ensuring adequate follow-up over a long period of time. Moreover, a sizable group of subjects is
required to adequately investigate a rare disease and control of peripheral variables may be
incomplete, resulting in increased bias [4, 37, 44, 45]. Finally, it is difficult to accurately account
for changes in medical treatment over time, resulting in the emergence of “temporal bias”.
Unsystematic personal observations, prior to the introduction of EBM, have carried great
weight in shaping both medical education and practice [15]. We now have a much better
appreciation of how these observations may be inherently biased and how much progress
was forfeited by perpetuating a system of subjective opinions in our current era of less biased,
objective scientific investigation [4]. Although the different limitations of various LSEs
discussed above may seem considerable, one must remember that they are dwarfed by the
potential harm resulting from unrestricted, non-evidenced practice of yesterday. As long as
practitioners and champions of healthcare quality and safety use a healthy degree of informed
caution when interpreting published evidence and clinical data, continued progress can be
made toward a better and safer, evidence-based medicine of tomorrow [2, 8].
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5. Evidence-based practice: focus on quality and safety
The practice of EBM is essential for making safe and effective clinical decisions and is also
crucial to promoting quality improvement and ensuring continuous focus on patient safety
in healthcare organizations [10, 25, 97]. Research is the foundation of the practice of EBM. It
helps drive enhanced health outcomes, promotes standardized approaches to care, and facili-
tates cost reduction in a resource-limited healthcare system [98–101]. Evidence for beneficial
effects of EBM continues to accumulate in a diverse number of allied health and medical areas
of specialty, including surgery, critical care, primary care and preventive medicine, internal
medicine and subspecialties, obstetrics and gynecology, as well as nursing, hospital adminis-
tration, health information technology, quality, and patient safety [102–106]. EBM can also be
formulated from patient-reported outcomes using established clinical processes such as The
Joint Commission Core Measures [107]. In addition, the Agency for Healthcare Research and
Quality (AHRQ) developed a series of quality indicators designed to standardize evidence-
based care medicine for preventing in-hospital complications that may result in penalties
under the auspices of value-based purchasing program [108]. Often, performance in standard-
ized quality indicators can be used to benchmark quality and safety performance in various
patient populations [108]. Preoperative prophylactic antibiotics, bowel preparation, and deep
vein thrombosis prophylaxis are examples of evidence-based best practices that have been
defined and protocolized by organizations and initiatives like Centers for Medicare & Medic-
aid Services (CMS) and the Surgical Care Improvement Project (SCIP) [109]. Similarly, check-
lists have revolutionized healthcare across increasing number of settings, as documented by
multiple studies demonstrating lower mortality, postoperative complication rates, and
enhanced adherence to patient safety procedures [110–115].
Patient safety research focuses on the identification of safety issues (e.g., patient safety gaps)
and their subsequent remediation through the study and implementation of new practices and
policies [113, 116]. Despite ample descriptive evidence, the implementation of safety practices
remains an underresearched subject, with much work remaining before achieving “zero inci-
dence” goals across many adverse event types [9, 117]. Perhaps more troubling is the observa-
tion that the gap between research findings and implementation across various clinical settings
may indeed be widening [102]. There is an estimated lag time of approximately 17 years from
research to implementation in clinical practice [118, 119]. It stands to reason that a better
process is required for this much needed translational process to occur more efficiently. For
example, since the mid-1800s, the importance of hand hygiene has been a widely accepted fact,
as numerous studies have confirmed the significant benefit of this practice. Despite the pres-
ence of widespread awareness and institutional guidelines, compliance among healthcare
workers and doctors in particular remains low [120, 121]. Dissemination and application of
evidence-based safety practices is often met with multiple obstacles and/or outright resistance,
both at the individual and organizational levels [8, 106]. In one systematic review of 23 studies
of stand-alone teaching of EBM principles in a postgraduate education setting, it was noted
that although knowledge increased, behaviors, attitudes, and skills did not change; and a
system of interactive teaching strategies was recommended [122]. Development of effective
policies based on carefully vetted research evidence constitutes another major barrier to the
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actual implementation of evidence into practice, especially within organizations where expert
opinion and hierarchical decision-making impose “glass ceilings” toward evidence-based
approaches. Moreover, numerous methodological and ethical complexities make research in
clinical safety particularly challenging, as patients cannot be subjected to blinding or random-
ization [102].
It is important to reiterate that EBM is not purely about conducting RCTs and implementing
their context-appropriate results into clinical practice. Evidence-based medicine extends to
critical decision-making regarding treatment and practices that stem from carefully and
thoughtfully considering and weighing “best evidence” [123–125]. Well-designed case-control
and cohort studies can prove to be equally effective tools and should be considered for areas
where RCTs are simply not feasible or impractical. Lastly, it is every practitioner’s obligation to
provide the best available care for their patients and that will continue to be driven by the
increasing wealth of available literature [126], hopefully characterized by better LSEs and
overall quality of both methodology and data. Practitioners and champions of patient safety
must therefore be encouraged to thoroughly search and evaluate published research and
thoughtfully consider “best evidence” in an unbiased, holistic manner before committing to
any clinical decisions or programmatic implementations.
Clinical pathways and guidelines are used by practitioners to provide a framework of care for
specific patient populations to improve outcomes [107]. Clinical guidelines are evidence-based
care recommendations for defined populations and assist the clinician in decision-making
regarding the patient care plan. Clinical pathways are used to implement the guidelines into
practice and represent what has been determined to be the best evidence-based care for most
patients [127]. They are typically a written tool and may be facility specific with an overarching
goal of minimizing variability and optimizing outcomes. Rotter et al. [128] reviewed 27 studies
involving 11,398 participants. Twenty of those studies compared clinical pathways with usual
care. Their review identified a reduction in complications and improved documentation. Most
studies also reported significant reductions in patient length of stay and thus a favorable
impact on associated costs [128].
6. Grades of recommendation
It has long been known that clinical practices based on scientific evidence can only be “as good
as” the underlying evidence and judgments [124]. Parallel to the assessment of LSE discussed
in previous sections of this manuscript, the need arose for the ability to grade the corres-
ponding recommendations—a necessary step for reconciliation of all of the components of,
and internal consistency of, EMB practices [124]. Grading of recommendations has been
pioneered by the Scottish Intercollegiate Guidelines Network (SIGN), with subsequent world-
wide embrace and adoption of this powerful healthcare quality improvement paradigm
[129, 130]. As outlined in Table 2, recommendations are graded on a scale from A (highest) to
C (lowest), with the overall goal of careful consideration and weighing of objective and
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subjective components of both the available evidence and its corresponding interpretation. It is
important to note that different other GOR paradigms have been devised, with the topic being
so vast as to warrant its own dedicated chapter and/or book [124]. Finally, another matter that
is beyond the scope of the current discussion is the advent of various reporting requirements
for different types of studies. The reader is referred to external resources for additional infor-
mation on this important and increasingly complex subject [131–134].
Another important development in the area of translating evidence into practice was the
introduction of the GRADE (Grading of Recommendations Assessment, Development, and
Evaluation) approach [135, 136]. In the GRADE paradigm, evidence is assessed in terms of
both its certainty (e.g., quality) and strength of the corresponding clinical recommendation(s)
[135, 137]. In terms of practical applicability of the GRADE system, quality of evidence and the
corresponding definitions are provided in Table 3 [138]. A multi-tiered system, examining
specific evidence-related factors and criteria in the context of their influence on the direction
and strength of the recommendation, is then employed to help with clinical implementations
and translations of research data [139]. Since its introduction, the GRADE paradigm provides a
well-organized and objectivized framework for evaluating the relative importance of research
outcomes and alternative clinical approaches, and summarizing evidence for systematic
reviews and clinical practice guidelines [139].
7. Synthesis: putting evidence to work, one improvement cycle at a time
The entirety of our previous discussion revolved around the levels of scientific evidence,
various aspects of their interpretation and implementation, as well as grades of recommenda-
tions outlined in the overall context of EBM-based discussion. At this point, it will be impor-
tant for the reader to become familiar with some of the methodologies employed in healthcare
quality and patient safety improvement efforts. It is critical to emphasize that these approaches
not only rely on EBM for planning and assessment but also help modify our existing EBM
patterns through a continuous process improvement cycle. While evidence-based medicine
has focused on providing the most recent evidence-based care for patients, quality improve-
ment has focused more on the way we provide that care [140]. The evidence must be reviewed
to ensure that it is indeed the right care while there also needs to be a clinical improvement
High High level of confidence regarding the true effect being close to that of the estimate of the effect
Moderate Moderate level of confidence regarding the effect estimate. In other words, the true effect is likely to
approximate the estimate of the effect, but non-trivial possibility exists of a “substantial difference”
Low There is low overall confidence that the effect estimate reflects the true effect. In other words, the true (actual)
effect may be substantially different from the estimated effect
Very low There is very little confidence that the effect estimate reflects the true effect. In other words, the true effect is
likely to be substantially different from the estimated effect
Table 3. Quality of evidence assessment definitions, as utilized in the GRADE approach [138].
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process to implement the change or evidence-based care. The two most common formats used
in the areas of healthcare quality improvement and patient safety are the PDCA (or Plan-
Do-Check-Act, Figure 2) and the 5A’s (Assess-Ask-Acquire-Appraise-Apply, Figure 3) meth-
odologies [141–147]. The goal of these performance improvement approaches is to achieve the
desired results and continue on to another part of the process [107].
8. Conclusion
Evidence-based medicine continues to evolve into a practical way of integrating feedback from
process outcomes and research results into clinical practice, assisting practitioners globally in
providing optimal care for their patients. Understanding the different levels of evidence and
the strength of recommendations is an integral component of EBM and helps guide decision
making, but must consistently be interpreted in the context of sound clinical judgment and a
strong therapeutic relationship with our patients. Champions of patient safety and care quality
should be familiar with and comfortable in the application of the above concepts in their
everyday practice. In addition, excellent knowledge of established standards for reporting
evidence, as well as key methodologies used in the process of guideline implementation, will
help guide clinicians toward providing the highest quality, safest possible care to their patients.
It is crucial to understand that no single study should be accepted as “fact” nor should any
study be disregarded based purely on its LSE. Instead, deliberate efforts should be made to
critically analyze recommendations and apply them judiciously, after careful consideration of
all available evidence has been made in the context of each specific clinical situation and
setting. It is essential that healthcare institutions undergo a cultural transformation to ensure
that evidence-based safety practices are introduced, effectively implemented, and allowed to
achieve their full potential and intended impact [101].
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